Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$13.19M-27.6%-$8.32M+27.1%-$11.8M+10.9%-$12.3M+0.4%-$10.34M+5.2%
$34K-8.1%$31K-18.4%$38K+5.6%$38K0.0%$37K+5.7%
$2.19M+81.4%$1.35M+47.2%$1.24M+51.2%$1.38M+22.8%$1.21M+67.1%
-$16.69M-23.8%-$7.63M+20.1%-$10.88M-13.9%-$10.1M-16.3%-$13.48M-28.8%
$102K$12K
$16.97M+270%-$30.61M-28.2%-$50.94M-764%-$2.61M-$9.95M-23.0%
$222K-97.4%$284K-99.4%$1.63M-67.3%$110.4M+2,079%$8.71M+31,189%
$498K+103%-$37.96M-310%-$60.19M-2,048%$97.68M+11,619%-$14.72M+20.8%
-$16.79M-$7.63M+20.2%-$10.89M-14.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Trevi Therapeutics, Inc. generate?
Trevi Therapeutics, Inc. (TRVI) generated -$45.3M in operating cash flow over the trailing twelve months.
What is Trevi Therapeutics, Inc.'s free cash flow?
After $143.0K of capital expenditures, Trevi Therapeutics, Inc.'s free cash flow was -$44.9M over the trailing twelve months, down 35.4% year over year.
Where does Trevi Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.